ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

The cost of treating depression in Canada has increased exponentially over the past two decades, far outpacing the growth in population, and leaving health economists to ponder a number of possible reasons for the increase. According to a study conducted by investigators from the University of Toronto, the number of prescriptions written for antidepressants increased by 353% between 1981 and 2000, from 3.2 million per year to 14.5 million per year, while Canada's population increased by an average of only 1% per year. Treating depression cost the Canadian economy an estimated $Can543.4 million*in 2000 in wholesale drug costs alone. It is further estimated that 850 000 Canadians will visit psychologists and other mental health professionals, excluding physicians, each year, at an approximate cost of $Can125 per visit.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Approximately 10% of patients with coronary artery disease (CAD) are ineligible for coronary artery bypass graft (CABG) surgery or angioplasty, and therefore require alternative treatment strategies. A potential therapeutic option for such patients is gene therapy. Results from REVASC, the first major randomised "proof of concept" study using a gene therapy agent, have demonstrated promising efficacy with a vascular endothelial growth factor (VEGF)-encoding adenoviral vector in patients with CAD who are not candidates for revascularisation. Data presented in a latebreaker session at the 75th Annual Scientific Sessions of the American Heart Association (AHA) [Chicago, US; November 2002] showed that AdGVVEGF121.10 ['BioBypass'] reduced ischaemia and significantly improved quality of life (QOL) in such patients. However, although AdGVVEGF121.10 itself was well tolerated, its administration via minithoracotomy and intramyocardial injection was associated with serious adverse events; thus, a catheter system will be used to deliver AdGVVEGF121.10 in future studies.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS